# Cardiovascular and Renal Outcomes Following Repeated Naringenin Exposure in Normotensive and Hypertensive Rats

**Authors:** Anelize Dada, Rita de Cássia Vilhena da Silva, Mariana Zanovello, Anelise Felício Macarini, Thaise Boeing, Valdir Cechinel Filho, Priscila de Souza

PMC · DOI: 10.3390/ph18060873 · Pharmaceuticals · 2025-06-12

## TL;DR

This study shows that naringenin, a compound in citrus fruits, lowers blood pressure and improves kidney function in both healthy and hypertensive rats.

## Contribution

The study demonstrates naringenin's potential as a natural treatment for hypertension and kidney disease through novel molecular targets like SGLT1 and SGLT2.

## Key findings

- Naringenin reduced blood pressure and increased diuresis in both normotensive and hypertensive rats.
- It reduced calcium oxalate crystal formation in urine and showed interactions with SGLT1/SGLT2 transporters.
- Molecular docking suggests naringenin interacts with MMP-9 and β2-adrenergic receptors, aiding crystal reduction.

## Abstract

Background: Systemic arterial hypertension is one of the leading global health concerns, significantly increasing the risk of cardiovascular and kidney diseases, including nephrolithiasis. The treatment, still far from ideal, is constantly undergoing new alternatives. In this context, medicinal plants rich in flavonoids, such as naringenin—a compound found in citrus fruits—have gained attention for their potential diuretic, nephroprotective, and blood pressure-lowering effects. Objectives: This study aimed to evaluate the effects of naringenin (100 mg/kg, orally) over nine days on blood pressure, renal function, and calcium oxalate crystal formation in normotensive Wistar (NTR) and spontaneously hypertensive male rats (SHR). Methods: Key assessments included blood pressure and heart rate measurements in vivo, urine volume and electrolyte excretion in vivo, in vitro calcium oxalate crystallization, and in silico molecular docking analyses to investigate molecular interactions. Results: Naringenin treatment significantly reduced blood pressure and increased diuresis in both NTR and SHR groups, while a notable natriuretic effect was observed specifically in NTR. In vitro, naringenin reduced the formation of calcium oxalate crystals in urines from NTR. Molecular docking studies suggested that these effects may be mediated by interactions with SGLT1 and SGLT2 transporters, potentially explaining the diuretic and natriuretic outcomes. Additionally, interactions with MMP-9 and β2-adrenergic receptors may contribute to the reduction in crystal formation. Conclusions: Collectively, these findings indicate that repeated administration of naringenin exerts beneficial effects on both cardiovascular and renal parameters, and point to promising molecular targets that may underlie its protective actions.

## Linked entities

- **Proteins:** SLC5A1 (solute carrier family 5 member 1), SLC5A2 (solute carrier family 5 member 2), MMP9 (matrix metallopeptidase 9)
- **Chemicals:** naringenin (PubChem CID 932), calcium oxalate (PubChem CID 33005)
- **Diseases:** nephrolithiasis (MONDO:0008171), cardiovascular disease (MONDO:0004995), kidney disease (MONDO:0001343)

## Full-text entities

- **Genes:** Slc5a2 (solute carrier family 5 member 2) [NCBI Gene 64522] {aka Sglt2}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 81687], Slc5a1 (solute carrier family 5 member 1) [NCBI Gene 25552] {aka SGLT1, SGLT1a}
- **Diseases:** Hypertensive (MESH:D006973), cardiovascular and kidney diseases (MESH:D007674), nephrolithiasis (MESH:D053040)
- **Chemicals:** Naringenin (MESH:C005273), flavonoids (MESH:D005419), calcium oxalate (MESH:D002129)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12196115/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12196115/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC12196115/full.md

---
Source: https://tomesphere.com/paper/PMC12196115